These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34675120)

  • 21. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
    O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
    Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
    Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
    Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
    PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
    Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer.
    Reebye V; Querol Cano L; Lavery DN; Brooke GN; Powell SM; Chotai D; Walker MM; Whitaker HC; Wait R; Hurst HC; Bevan CL
    Mol Endocrinol; 2012 Oct; 26(10):1694-706. PubMed ID: 22899854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hsp90: still a viable target in prostate cancer.
    Centenera MM; Fitzpatrick AK; Tilley WD; Butler LM
    Biochim Biophys Acta; 2013 Apr; 1835(2):211-8. PubMed ID: 23287571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
    Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.
    Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM
    Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer.
    Rice MA; Kumar V; Tailor D; Garcia-Marques FJ; Hsu EC; Liu S; Bermudez A; Kanchustambham V; Shankar V; Inde Z; Alabi BR; Muruganantham A; Shen M; Pandrala M; Nolley R; Aslan M; Ghoochani A; Agarwal A; Buckup M; Kumar M; Going CC; Peehl DM; Dixon SJ; Zare RN; Brooks JD; Pitteri SJ; Malhotra SV; Stoyanova T
    Cell Rep Med; 2022 Feb; 3(2):100502. PubMed ID: 35243415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression.
    Akalin A; Elmore LW; Forsythe HL; Amaker BA; McCollum ED; Nelson PS; Ware JL; Holt SE
    Cancer Res; 2001 Jun; 61(12):4791-6. PubMed ID: 11406554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heat shock protein 90 is associated with hyperplasia and neoplastic transformation of canine prostatic epithelial cells.
    Palmieri C; Mancini M; Benazzi C; Della Salda L
    J Comp Pathol; 2014 May; 150(4):393-8. PubMed ID: 24679854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
    Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
    Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
    Saporita AJ; Ai J; Wang Z
    Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma.
    Hoang AT; Huang J; Rudra-Ganguly N; Zheng J; Powell WC; Rabindran SK; Wu C; Roy-Burman P
    Am J Pathol; 2000 Mar; 156(3):857-64. PubMed ID: 10702402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
    Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
    Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor.
    Harashima K; Akimoto T; Nonaka T; Tsuzuki K; Mitsuhashi N; Nakano T
    Int J Radiat Biol; 2005 Jan; 81(1):63-76. PubMed ID: 15962764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90.
    Aalinkeel R; Bindukumar B; Reynolds JL; Sykes DE; Mahajan SD; Chadha KC; Schwartz SA
    Prostate; 2008 Dec; 68(16):1773-89. PubMed ID: 18726985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hsp90 as a therapeutic target in prostate cancer.
    Solit DB; Scher HI; Rosen N
    Semin Oncol; 2003 Oct; 30(5):709-16. PubMed ID: 14571418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
    Cha TL; Qiu L; Chen CT; Wen Y; Hung MC
    Cancer Res; 2005 Mar; 65(6):2287-95. PubMed ID: 15781642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.